menu
    • menu

    Company profile for Immunicom

    NEW Drugs in Dev: 1
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immunicom’s is designed to empower patients to best live their lives while receiving revolutionary cancer treatment. This unique immunotherapy is intended to meaningfully improve patients’ quality of life and avoid typical side-effects. A transformative immunotherapy Immunicom creates novel immunotherapies designed to treat a variety of diseases using Immunicom’s breakthrough Immunopheresis™ technology platform. T...
    Immunicom’s is designed to empower patients to best live their lives while receiving revolutionary cancer treatment. This unique immunotherapy is intended to meaningfully improve patients’ quality of life and avoid typical side-effects. A transformative immunotherapy Immunicom creates novel immunotherapies designed to treat a variety of diseases using Immunicom’s breakthrough Immunopheresis™ technology platform. The breakthrough Immunopheresis approach uses a therapeutic device that works outside of the body and is designed to treat cancer, inflammatory, renal, and autoimmune diseases by removing barriers from the blood.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmunicomUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    6048 Cornerstone Court W Suite D San Diego, CA 92121
    Telephone
    Telephone
    (657) 202-6388
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://immunicom.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immunicom/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    International Sweetener Colloquium

    Not Confirmed

    envelop Contact Supplier

    International Sweetener Colloquium

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immunicom Receives NIH/NCI Grant for First US-Based Trial at Baylor
    Immunicom Receives NIH/NCI Grant for First US-Based Trial at Baylor

    15 Jun 2022

    // TRIALSITENEWS

    https://www.trialsitenews.com/a/immunicom-receives-nihnci-grant-for-first-us-based-trial-at-baylor-in-refractory-erher2-breast-cancer-patients-0007f9ee

    TRIALSITENEWS
    15 Jun 2022
    Share Share
    Immunicom Clinical Trial Data at ASCO 2022 Show Immunopheresis LW-02 Column
    Immunicom Clinical Trial Data at ASCO 2022 Show Immunopheresis LW-02 Column

    02 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220602005917/en

    BUSINESSWIRE
    02 Jun 2022
    Share Share
    Immunicom Presents New Data at AACR of LW-02 Cartridge Immunopheresis Therapy
    Immunicom Presents New Data at AACR of LW-02 Cartridge Immunopheresis Therapy

    28 Apr 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220428006112/en

    BUSINESSWIRE
    28 Apr 2022
    Share Share
    Immunicom Appoints Dr. Annette Marleau as Chief Technology Officer
    Immunicom Appoints Dr. Annette Marleau as Chief Technology Officer

    17 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220217005281/en

    BUSINESSWIRE
    17 Feb 2022
    Share Share
    Immunicom Announces Promising Preliminary Data from its Immunopheresis Study
    Immunicom Announces Promising Preliminary Data from its Immunopheresis Study

    07 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211207005449/en

    BUSINESSWIRE
    07 Dec 2021
    Share Share
    Terumo, Immunicom Sign Agreement to Launch Breakthrough Cancer Immunotherapy
    Terumo, Immunicom Sign Agreement to Launch Breakthrough Cancer Immunotherapy

    16 Nov 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/terumo-blood-and-cell-technologies-and-immunicom-establish-agreement-to-launch-breakthrough-cancer-immunotherapy-treatment-in-europe-301425124.html

    PRNEWSWIRE
    16 Nov 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search